These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37816181)

  • 1. Excipients and Adverse Events.
    Allen LV
    Int J Pharm Compd; 2023; 27(5):382-385. PubMed ID: 37816181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excipient Stability in Oral Solid Dosage Forms: A Review.
    Darji MA; Lalge RM; Marathe SP; Mulay TD; Fatima T; Alshammari A; Lee HK; Repka MA; Narasimha Murthy S
    AAPS PharmSciTech; 2018 Jan; 19(1):12-26. PubMed ID: 28895106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review.
    Caballero ML; Quirce S
    J Investig Allergol Clin Immunol; 2020; 30(6):400-408. PubMed ID: 32376520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview of Pharmaceutical Excipients: Safe or Not Safe?
    Abrantes CG; Duarte D; Reis CP
    J Pharm Sci; 2016 Jul; 105(7):2019-26. PubMed ID: 27262205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridging the Gap: A Comparative Investigation of Pharmaceutical Excipient Regulations.
    Mali A; Kuvar V; Bharadwaj S
    Ther Innov Regul Sci; 2024 Mar; 58(2):258-272. PubMed ID: 38055157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyzing excipient-related adverse events in antiseizure drug formulations.
    Ionova Y; Peterson T; Wilson L
    Epilepsy Res; 2022 Aug; 184():106947. PubMed ID: 35661571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best practices for selection of excipients for paediatrics - Workshop reflection.
    Salunke S; Clapham D; Agrawal A; Hughes K; Nunn T
    Eur J Pharm Biopharm; 2021 Mar; 160():77-81. PubMed ID: 33400989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part I).
    Golightly LK; Smolinske SS; Bennett ML; Sutherland EW; Rumack BH
    Med Toxicol Adverse Drug Exp; 1988; 3(2):128-65. PubMed ID: 3287089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excipients and additives: hidden hazards in drug products and in product substitution.
    Napke E; Stevens DG
    Can Med Assoc J; 1984 Dec; 131(12):1449-52. PubMed ID: 6498699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical Excipient Exposure in a Neonatal Intensive Care Unit.
    Nasrollahi S; Meera NK; Boregowda S
    Indian Pediatr; 2020 Sep; 57(9):801-804. PubMed ID: 32999107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harmful excipients in medicines for neonates in Spain.
    Garcia-Palop B; Movilla Polanco E; Cañete Ramirez C; Cabañas Poy MJ
    Int J Clin Pharm; 2016 Apr; 38(2):238-42. PubMed ID: 26960405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitigating unwanted amorphisation: A screening method for the selection of suitable excipients.
    Amharar Y; Curtin V; Gallagher KH; O'Siochru E; O'Connell P; Healy AM
    Eur J Pharm Sci; 2016 Jan; 81():181-8. PubMed ID: 26493586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.
    Wu Y; Levons J; Narang AS; Raghavan K; Rao VM
    AAPS PharmSciTech; 2011 Dec; 12(4):1248-63. PubMed ID: 21948318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
    Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
    Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review.
    Caballero ML; Quirce S
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):86-100. PubMed ID: 32327401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics.
    Rayaprolu BM; Strawser JJ; Anyarambhatla G
    Drug Dev Ind Pharm; 2018 Oct; 44(10):1565-1571. PubMed ID: 29863908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basics: Excipients Used in Nonsterile Compounding, Part 3: Preservatives.
    Allen LV
    Int J Pharm Compd; 2019; 23(6):472-477. PubMed ID: 31751944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activities of drug inactive ingredients on biological targets.
    Pottel J; Armstrong D; Zou L; Fekete A; Huang XP; Torosyan H; Bednarczyk D; Whitebread S; Bhhatarai B; Liang G; Jin H; Ghaemi SN; Slocum S; Lukacs KV; Irwin JJ; Berg EL; Giacomini KM; Roth BL; Shoichet BK; Urban L
    Science; 2020 Jul; 369(6502):403-413. PubMed ID: 32703874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines.
    Caballero ML; Quirce S
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):92-93. PubMed ID: 33433387
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk of error estimated from Palestine pharmacists' knowledge and certainty on the adverse effects and contraindications of active pharmaceutical ingredients and excipients.
    Shawahna R; Al-Rjoub M; Al-Horoub MM; Al-Hroub W; Al-Rjoub B; Al-Nabi BA
    J Educ Eval Health Prof; 2016; 13():1. PubMed ID: 26743774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.